Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03927222 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
A Phase 2 study, sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03927222: Clinical Trial Phase 2 study, sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP.
NCT03927222 is a Phase 2 study that was terminated before completion, run by Mustafa Khasraw, MBChB, MD, FRCP, FRACP. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03927222, a Phase 2 study, was terminated before completion, sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This single-arm phase II study will assess the impact of tetanus pre-conditioning and adjuvant Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) on overall survival of patients newly diagnosed with World Health Organization (WHO) Grade IV glioblastoma who have undergone definitive tumor resection, are cytomegalovirus (CMV) positive and unmethylated, and completed standard temozolomide (TMZ) and radiation treatment. After completion of the standard of care radiotherapy with concurrent TMZ, patients will receive 1 cycle of dose-intensified TMZ followed by pp65-loaded dendritic cell (DC) vaccination beginning on day 23.
Primary Outcome
Time in months from the start of study treatment to date of death due to any cause. Patients alive as of the last follow-up has OS censored at the last follow-up date. Median OS was estimated using a Kaplan-Meier curve.
Interventions
- DRUG Temozolomide
- BIOLOGICAL GM-CSF
- BIOLOGICAL Tetanus-Diphtheria Toxoid (Td)
- BIOLOGICAL Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF
- BIOLOGICAL 111-Indium-labeling of Cells for in vivo Trafficking Studies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2023-02-10 |
| Phase | Phase 2 |
Why NCT03927222 stopped before completion
NCT03927222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Temozolomide is the first listed.
NCT03927222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03927222 about?
NCT03927222 is a clinical study titled "Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma". This single-arm phase II study will assess the impact of tetanus pre-conditioning and adjuvant Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) on overall survival of patients newly diagnosed with World Health Organization (WHO) Grade IV glioblastoma who have undergone definitive tumor rese...
What is the current status of trial NCT03927222?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-09-30. Estimated completion is 2023-02-10.
What interventions are being tested in trial NCT03927222?
The interventions under investigation include: Temozolomide (DRUG), GM-CSF (BIOLOGICAL), Tetanus-Diphtheria Toxoid (Td) (BIOLOGICAL), Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF (BIOLOGICAL), 111-Indium-labeling of Cells for in vivo Trafficking Studies (BIOLOGICAL).
Who is sponsoring clinical trial NCT03927222?
This trial is sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03927222's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI